Table 1.
Patient baseline characteristics and clinical demographics, stratified by long-term use of VEDO treatment as a surrogate outcome for sustained response to treatment.
| Continued Use (n = 17) |
Discontinued Use (n = 15) | p | |
|---|---|---|---|
| Age (years) | 41 [35–60] | 42 [35–60] | >0.999 |
| Gender | 0.444 | ||
| Female | 6 (35%) | 3 (20%) | |
| Male | 11 (65%) | 12 (80%) | |
| BMI (kg/m2) | 22.6 [21.0–25.0] | 24.2 [20.9–26.9] | 0.509 |
| Smoking | 0.134 | ||
| No | 5 (29%) | 10 (67%) | |
| Previous | 4 (24%) | 2 (13%) | |
| Current | 8 (47%) | 3 (20%) | |
| Montreal classification | |||
| Montreal Age (A) | 0.886 | ||
| A1 (≤16 years) | 2 (12%) | 3 (20%) | |
| A2 (17–40 years) | 11 (65%) | 8 (53%) | |
| A3 (>40 years) | 4 (24%) | 4 (27%) | |
| Montreal Location (L) | 0.501 | ||
| L1 (ileal disease) | 4 (24%) | 2 (13%) | |
| L2 (colonic disease) | 1 (5.9%) | 3 (20%) | |
| L3 (ileocolonic) | 12 (71%) | 10 (67%) | |
| L4 (upper GI disease) | 0 (0%) | 0 (0%) | |
| Montreal Behavior (B) | 0.553 | ||
| B1 (non-stricturing, non-penetrating) | 5 (29%) | 5 (33%) | |
| B2 (stricturing) | 8 (47%) | 4 (27%) | |
| B3 (penetrating) | 4 (24%) | 6 (40%) | |
| Montreal Perianal disease (p) | 5 (29%) | 4 (27%) | >0.999 |
| Medication use, n (%) | |||
| Aminosalicylates | 0 (0%) | 2 (13%) | 0.212 |
| Steroids | 9 (53%) | 9 (60%) | 0.688 |
| Immunosuppressives | 9 (53%) | 4 (27%) | 0.131 |
| Prior anti-TNF-α | 15 (88%) | 15 (100%) | 0.486 |
| Prior Vedolizumab | 0 (0%) | (0%) | NA |
| Surgical history | |||
| Colectomy | 0 (0%) | 1 (6.7%) | 0.469 |
| Ileocecal resection | 11 (65%) | 9 (60%) | 0.784 |
| Clinical disease activity | |||
| Harvey-Bradshaw Index (HBI) | 0.866 | ||
| Remission (<5) | 1 (7.1%) | 2 (17%) | |
| Mild disease (5–7) | 6 (43%) | 4 (33%) | |
| Moderate disease (8–16) | 7 (50%) | 6 (50%) | |
| Severe disease (>16) | 0 (0%) | 0 (%) | |
| Clinical parameters | |||
| Hemoglobin (nmol/L) | 7.60 [7.00–8.20] | 7.50 [7.20–7.95] | 0.583 |
| WBC (×109/L) | 7.3 [6.4–9.1] | 9.4 [5.0–12.3] | 0.821 |
| Neutrophil count (×109/L) | 4.91 [3.96–5.83] | 5.54 [3.17–8.98] | 0.796 |
| Eosinophil count (×109/L) | 0.16 [0.03–0.24] | 0.09 [0.05–0.17] | 0.404 |
| CRP (mg/L) | 2 [1–6] | 14 [8–26] | 0.001 |
| Creatinine (µmol/L) | 61 [49–71] | 67 [59–72] | 0.508 |
| eGFR (mL/min/1.73 m2) | 108 [94–120] | 104 (82–122] | 0.664 |
| Fecal calprotectin (µg/g) ^ | 982 [658–1455] | 1400 [852–1825] | 0.475 |
Data are presented as median [IQR] for continuous variables or as proportions n with corresponding percentages (%) for categorical variables. ^ Fecal calprotectin levels were available for n = patients.